Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Sana Biotechnology Q3 2026 Results: Turns Profitable, Net Income $20.4M

Sana Biotechnology reported a net loss of $90.4 million for the nine months ended September 30, 2026, a significant improvement from the $185.3 million loss in the prior year period. The company achieved a net income of $20.4 million in the third quarter of 2026, primarily driven by a $63.4 million gain from the revaluation of research and development related success payments and contingent consideration.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income20.4-42.2
EPS (diluted, $ a share)$0.07$-0.16

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: SANA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Sana Biotechnology, Inc.: key numbers

Share price
$1.88Close, Nov 16
Market cap
$563M
Shares outstanding
299.63MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Sana Biotechnology, Inc.

All →
4:11 PM ET 8-K
Financial Results

Sana Biotechnology Financial Results

Sana Biotechnology reported third quarter 2026 financial results, highlighting a cash position of $121.7 million and a cash runway expected to last into mid-2027. The company is progressing toward initiating clinical trials for its type 1 diabetes candidate SC451 and its non-Hodgkin lymphoma candidate SG293, with data readouts anticipated in 2027.

“We continue to make meaningful progress toward initiating clinical studies of SC451 later this year and SG293 in 1Q 2027. We aim to share data from both of these programs in 2027 and anticipate both have the potential for relatively rapid proof of concept. In particular, SC451 in type 1 diabetes may provide a rapid signal, similar to what was seen with UP421, on whether the therapy can evade immune detection and function in patients.”

Steve Harr, Sana’s President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.